Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on November 5, 2015, regarding events occurring on November 6, 2015. The filing discloses the entry into a Material Definitive Agreement for a registered direct offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $7.0 million.
- Net Proceeds: Approximately $6.5 million (after deducting placement agent fees, expenses, and estimated offering costs).
- Securities Issued: 16,666,667 shares of common stock and warrants exercisable for up to 12,500,000 shares.
- Offering Price: $0.42 per unit (one share plus a warrant for 0.75 shares).
- Warrant Terms: Exercise price of $0.53 per share; exercisable beginning six months after issuance; expire five years from the initial exercise date.
- Placement Agent Fees: 6% of gross proceeds plus a warrant for approximately 833,333 shares (5% of shares sold) and $50,000 in expenses.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement with a single institutional investor. The agreement includes a 12-month right of participation for the investor, allowing them to purchase up to 30% of any subsequent financing of common stock or debt securities on the same terms. The offering is expected to close on or about November 11, 2015, subject to customary closing conditions.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance, revenue projections, or management commentary regarding future operations beyond the closing of this offering. The transaction is contingent upon the satisfaction of customary closing conditions. The filing explicitly states that the representations and warranties in the agreements are not intended as factual information for the public regarding the current state of affairs of the company.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected November 11, 2015) and confirm receipt of net proceeds.
- Review the effective shelf registration statement (Form S-3, File No. 333-196255) for the prospectus supplement details.
- Monitor for any subsequent financing events within the 12-month window to assess the investor's right of participation.
- Confirm the final dilution impact of the 16,666,667 shares and 12,500,000 warrant shares on existing shareholders.
- Check for any updates on the company's cash runway and operational milestones post-funding.